![]() ![]() Exploratory path models revealed that final depression outcomes were more strongly affected by emotional breakthrough during the first, and mystical experience during the second session. Results: The strength of therapeutic alliance predicted pre-session rapport, greater emotional-breakthrough and mystical-type experience (maximum EBI and MEQ scores across the two psilocybin sessions) and final QIDS scores ( β = −0.22, R 2 = 0.42 for EBI Max β = −0.19, R 2 = 0.32 for MEQ Max). The same analysis was performed on the escitalopram arm to test specificity. Path analyses tested the hypothesis that therapeutic alliance (Scale To Assess the Therapeutic Relationship Patient Version, STAR-P) would predict depression outcomes via its influence on the acute psychedelic experience, specifically emotional-breakthrough (EBI) and mystical-type experiences (MEQ). The primary outcome was depression severity 6 weeks post treatment (Quick Inventory of Depressive Symptomatology, QIDS-SR-16). A new psychedelic therapy model, called “Accept-Connect-Embody” (ACE), was developed in this trial. This analysis focused on the psilocybin condition ( n = 30), who received two oral doses of 25 mg psilocybin, 3-weeks apart, with psychological preparation, in-session support, and integration therapy. Methods: This 2-arm double-blind randomized controlled trial compared escitalopram with psychedelic-assisted therapy for moderate-severe depressive disorder ( N = 59). ![]() We aimed to investigate the relationships between therapeutic alliance and rapport, the quality of the acute psychedelic experience and treatment outcomes. 6Psychedelics Division Neuroscape, Department of Neurology, University of California, San Francisco, San Francisco, CA, United Statesīackground: Across psychotherapeutic frameworks, the strength of the therapeutic alliance has been found to correlate with treatment outcomes however, its role has never been formally assessed in a trial of psychedelic-assisted therapy.5Department of Psychology, Royal Holloway University, Surrey, United Kingdom.4Medical Psychotherapy and General Adult Psychiatry, Devon Partnership NHS Trust, Exeter, United Kingdom.3Department of Psychology, Ryerson University, Toronto, ON, Canada.Georges NHS Trust, London, United Kingdom 2Medical Psychotherapy, South West London and St.1Department of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.Our Depression Recognition and Treatment package (DepReT-stroke) may help clinicians be more effective at detecting and managing a common co-morbidity that limits rehabilitation and recovery.Roberta Murphy 1,2*, Hannes Kettner 1, Rick Zeifman 1,3, Bruna Giribaldi 1, Laura Kartner 1, Jonny Martell 1,4, Tim Read 1, Ashleigh Murphy-Beiner 1,5, Michelle Baker-Jones 1, David Nutt 1, David Erritzoe 1, Rosalind Watts 1 † and Robin Carhart-Harris 1,6 † Discussion Depression both for patients and their carers is common after stroke. An economic evaluation of the intervention will help us determine whether the intervention represents a cost-effective use of resources. Effectiveness of the intervention will be determined using analysis of co-variance comparing the mean change in MCS scores from baseline to six months follow-up adjusting for the clustering effects of baseline scores and family. The primary outcome will be the Mental Component Subscale of the SF-36 assessed at baseline and again six months post intervention. An essential component of the DepReT-Stroke package will be to help people adhere to their chosen treatment(s). computerised Cognitive Behavioural Therapy or exercise). The DepReT-Stroke intervention will help families to consider the various treatment options for depression, make choices about which are likely to fit best with their lives and support them in the use of self-help therapies (e.g. We aim to recruit one hundred and twenty-six families (63 in each group). Methods A single blind cluster randomised controlled trial to evaluate whether families after stroke who are treated with the Depression Recognition and Treatment package (DepReT-Stroke) in addition to treatment as usual (TAU) show improved mental well being compared to those families who receive only TAU. ![]() We argue that working with families, rather than patients alone may improve the treatment of depression in both patients and their carers enhancing the mental wellbeing and quality of life of both. Mood disorders are also highly prevalent in carers their mental health intertwined with the physical and mental wellbeing of the person they are caring for. Background Depression occurs in up to 50% of patients after stroke and limits rehabilitation and recovery. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |